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Letters to the Editor128artery disease (CAD), an area of research in need of long term follow up
studies like this one (mean follow-up 4 years).
However, we noticed that the mean pre-test probability of CAD
n the study population was 42.5%, with one-quarter of the patients
aving a high CAD probability, which is not in line with the most
avored low-to-intermediate probability population referred for
TA for the exclusion of possible CAD (2), and that could explain
he higher-than-expected hard event rate for a stable CAD popu-
ation (almost 1 out of 2 patients with obstructive CAD dying or
aving a nonfatal myocardial infarction [MI]) in the follow-up (3).
This could have been the result of having included patients
admitted to the hospital because of new-onset chest pain (43%), a
subset that could be considered as possible acute coronary syndrome
(ACS) unstable angina/non–ST-segment elevation MI) and can
explain the higher than expected rate of major (death/MI) events in
the follow-up (event-free survival of 54%). In how many cases was
an ACS diagnosis confirmed? If any, the authors should have
excluded these patients from the study. We fully agree that CTA
can provide useful prognostic information beyond the exclusion of
obstructive CAD, but the inclusion of patients with possible ACS
and high CAD probability could have lead to an overestimation of
the prognostic power of CTA.
Another striking point was the fact that 45% of patients had
hypercholesterolemia but only 26% were treated with statins. Further,
statins turned out in multivariable analysis to be independent predic-
tors for hard events. Likewise, 26% of the population (with suspected
CAD) was taking aspirin, which is not generally recommended as
primary prevention. Use of aspirin was also an independent predictor
of all cardiac events. It would have been interesting to know if the use
of these drug groups is allocated to a more severe subset of patients
(more frequently used in obstructive vs. nonobstructive vs. normal
patients) and in this way are just a surrogate marker of higher disease
burden. Likewise, it would be of interest to know if patients were
already taking these drugs before the CTA or if they were just started
after significant disease was identified and, in this way, they could not
have had enough time to come out with its protective effects in a more
severe CAD subgroup of patients.
The Framingham risk score (FRS) was used to estimate the
cardiovascular risk of this Italian cohort of patients; it could have
been more accurately estimated with the European-based
HeartScore (4). This could have also influenced the results, as the
multivariable analysis models were adjusted for the FRS.
It is not mentioned that the events were independently adjudi-
cated and that the adjudication event committee is an experienced
one with acceptable intra-committee reproducibility for the adju-
dication of events. This point is of utmost relevance in a report of
this nature. In addition, regarding revascularizations, we agree that
early revascularizations should be excluded to avoid the influence of
CTA results in patient management but most of the previous
studies considered early as 30 days (5) and not 6 months like in the
paper from Andreini et al. (1). This could have also influenced the
results, as revascularizations in obstructive CAD group are likely to
have happened sooner after the CTA and in this regard could have
underestimated the prognostic value of obstructive versus nonob-
structive CAD. Further, it is not mentioned whether the revascu-arizations were ischemia-driven (i.e., only for obstructive lesions)
r not.
Despite the fact that authors have scored hierarchically the
laque type per segment (i.e., in case of presence of 2 plaques,
alcified and noncalcified, only one was scored and labeled as
alcified) which underestimates the frequency of noncalcified
laques, in the univariate analysis, these were found to be indepen-
ent predictors of hard events. This methodology seems to us to be
ounterintuitive, since it has been reported many times that
igh-risk plaques (i.e., plaques prone to rupture and associated with
n event) are those noncalcified or mixed, which could have come
ut as strong predictors also in the multivariate analysis if the
uthors had not underscored them.
Undoubtedly, this is a report with an important message, but we
eel that the above-mentioned points should be further explained to
trengthen the conclusions.
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The comments of Garcia-Garcia and Goncalves are relevant and
















J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 1 , 2 0 1 3
J A N U A R Y 2 0 1 3 : 1 2 4 – 3 0
Letters to the Editor 129a relatively high cumulative event rate at follow-up in multidetector
computed tomography coronary angiographic (MDCT-CA) ob-
structive coronary artery disease compared with other studies,
which may be due to characteristics of patients who had chest pain
and positive stress tests in 43% and 29% of cases, respectively.
However, the CONFIRM registry demonstrated that MDCT-CA
has the best prognostic value in this patient subset, whereas its value
in asymptomatic patients is quite limited (2). We agree that
including patients with acute coronary syndromes (ACS) may lead
to an overestimation of MDCT-CA prognostic capability. Accord-
ingly, we excluded patients in whom ACS was confirmed by cardiac
enzyme or electrocardiographic changes. The discrepancy between
hypercholesterolemia rate and statin use in our patients is in
agreement with the suboptimal therapy adherence reported in a
substantial proportion of European patients (3). Medical therapy
reported in our patients was administered before MDCT-CA.
Indeed, 26% of them were taking aspirin, not for CAD but for
other indications. We agree that the European Heart Score would
have been more appropriate than Framingham cardiovascular risk
estimation. However, the former has been challenged because it is
not mathematically consistent and unfit to estimate cardiovascular
mortality (4). In the first version of our paper, revascularizations
were defined “early” if performed within 2 months after MDCT-
CA. However, a reviewer criticized this definition. Indeed, using a
2-month cutoff, only 6 patients were excluded despite 295 patients
having MDCT-CA stenosis 70%. This indicates that many
revascularizations occurring later than 60 days were probably driven
by MDCT-CA. We agree that the 6-month cutoff may have led to
an underestimation of obstructive CAD prognostic value. However,
this limitation did not affect hard cardiac events survival analysis.
Finally, we believe that assigning 1 coronary plaque per coronary
segment and classifying a plaque as calcific in cases in which a
coronary segment contained calcific and noncalcific plaques was
correct, as previously reported (5). Indeed, in the presence of small
plaques, those calcific plaques are the easiest to detect with
MDCT-CA, and most prognostic data are based on simple
coronary plaque scores, regardless of plaque composition (3).
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Ultrasonographic Measure of
Carotid Plaque Burden
In their excellent paper, Sillesen et al. (1) omitted mention of the
original work on measurement of carotid plaque burden. Spence et
al. (2) first measured carotid total plaque area (TPA) in 1990, and
developed it for patient management and genetic research, and
3-dimensional methods for evaluation of new therapies. They
showed that TPA and progression of TPA strongly predicted the
5-year risk of stroke, death, or myocardial infarction after adjusting
for coronary risk factors.
Sillesen et al. (1) stated that the prevalence of plaque they observed
(78%) was 2-fold higher than previously reported. However, in the
NOMAS (Northern Manhattan Study) study, a population-based
study of individuals free of stroke at similar ages, plaque prevalence was
58% on 2-dimensional ultrasound imaging and it was greater by age
and among certain race-ethnic groups (3). Prevalence of plaque
epends on age and how it is defined. If defined as a focal thickening
1 mm, in vascular patients it increases from 75% of patients at age 35 to
5 years to 99% by age 65 to 75 years, and 100% over age 75 years (2).
Besides plaque burden, other ultrasonographic characteristics of
laque morphology such as plaque surface irregularity, ulceration,
exture, and plaque density may be even more important predictors
f stroke and cardiovascular disease.
The Tromsø study showed that TPA was a stronger predictor of
yocardial infarction and stroke (4) than intima-media thickness,
nd this was confirmed in a meta-analysis (5). Three-dimensional
laque volume is highly correlated with TPA, and is much more
ensitive to change with therapy than intima-media thickness or
PA, so it is the best way to assess effects of new therapies (2).
here is little doubt that carotid plaque burden will be a stronger
redictor of cardiovascular events in the High Risk Plaque Bioim-
ging Study than any of the other imaging modalities measured,
ith the possible exception of coronary calcium.
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